Clinical Trial

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-08.
Status change: Recruiting → Active, Not Recruiting 2025-06-27
Trial Details
NCT Number NCT06212297
Lead Sponsor Innostellar Biotherapeutics Co.,Ltd
Conditions Inherited Retinal Dystrophy
Enrollment 9 participants
Start Date 2023-09-12
Primary Completion 2025-02-06 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-29